Analysis of SOX9 Expression in Colorectal Cancer
Analysis of SOX9 Expression in Colorectal Cancer
复制标题
DOI：
10.1309/ajcpw1w8gjbqgcni
复制
发表时间：
2008-12-01
影响因子：
3.5
通讯作者：
Lai, Maode
中科院分区：
文献类型：
--
作者：
Lue, Bingjian;Fang, Yihu;Lai, Maode
我们的目的是研究一种新的β-连环蛋白下游分子SOX9在结直肠癌中的作用。采用免疫组织化学染色、实时定量逆转录聚合酶链式反应(Q-PCR)和Western印迹等方法检测SOX9和β-catenin在结直肠癌组织中的表达。分析SOX9和P-catenin的表达与临床病理参数的关系。免疫染色、Q-PCR和Western印迹一致证实SOX9在结直肠癌中的表达高于正常粘膜(P<；0.05)。免疫组织化学染色显示结肠隐窝下部SOX9+细胞较上部多(P<；0.05)。SOX9表达强的癌症与较低的5年总生存率显著相关(40%[17/43]vs低表达69%[66/95]；P<；.01)。COX比例风险模型显示SOX9强表达是结直肠癌的独立不良预后因素(P<；0.05)。检测SOX9的表达可能有助于预测结直肠癌患者的临床预后。
Our purpose was to investigate the role of SOX9, a novel downstream molecule of beta-catenin, in colorectal cancer. Expression of SOX9 and beta-catenin was detected by immunostaining, quantitative real-time reverse transcription-polymerase chain reaction (Q-PCR), and Western blot in colorectal cancer. The correlation between SOX9 or P-catenin expression and clinicopathologic parameters was also analyzed. Immunostaining, Q-PCR, and Western blot consistently confirmed SOX9 up-regulation in colorectal cancer compared with normal mucosa (P < .05). Immunostaining showed more SOX9+ cells in the lower zone of colonic crypts than in the upper zone (P < .05). Cancers with strong SOX9 immunostaining were significantly associated with a lower 5-year overall survival (40% [17/43] vs low expression, 69% [66/95]; P < .01). The Cox proportional hazards model showed that strong SOX9 expression was an independent adverse prognosticator in colorectal cancer (P < .05). The detection of SOX9 expression might contribute to predicting clinical outcomes for patients with colorectal cancer.